Founded in 1959 by its current Editor, the series has moved from its initial focus on medicinal chemistry to a much wider scope. Today it encompasses all fields concerned with the development of new therapeutic drugs and the elucidation of their mechanisms of action, reflecting the increasingly complex nature of modern drug research. Invited authors present their biological, chemical, biochemical, physiological, immunological, pharmaceutical, toxicological, pharmacological and clinical expertise in carefully written reviews and provide the newcomer and the specialist alike with an up-to-date comprehensive list of prime references. Each volume of Progress in Drug Research contains fully cross-referencing indices which link the books together, forming a virtually encyclopaedic work. The series thus serves as an important, time-saving source of information for researchers concerned with drug research and all those who need to keep abreast of the many recent developments in the quest for new and better medicines.

Volume 40 of "Progress in Drug Research" contains six reviews and the various indexes which facilitate its use and establish the connec tion with the previous volumes. The articles in this volume deal with phosphodiesterase inhibitors and their therapeutic potential in asthma; peptide receptor ligand drugs; aldose reductase inhibitors; the design and discovery of new drugs by stepping-down and stepping-up approaches; new synthetic ligands for L-type voltage gated calcium channels and with luteolytic agents in fertility regula tion. III the 33 years that "Progress in Drug Research" has existed, the Edi tor has enjoyed the valuable help and advice of many colleagues. Readers, the authors of the reviews, and last but not least, the review ers have all contributed greatly to the success of this series. Although the comments received so far have generally been favorable, it is nevertheless necessary to analyze and to reassess the current position and the future direction of such a review series.

Volume 41 of "Progress in Orug Research" contains eight reviews and the various indexes which facilitate its use and establish the con nection with the previous volumes. The articles in this volume deal with teratogenesis; nephrotoxicity; bacterial resistance to P. lactam antibiotics; eradication of diseases by vaccination; chirality and drug design; endogenous digitalis-like factors; erythropoietin; and sero tonin (5HT)-antagonists. 3 All these articles give an excellent overview of the respective fields of research. In the 33 years that POR has existed, the Editor has enjoyed the valu able help and advice of many colleagues. Readers, the authors of the reviews, and last but not least, the reviewers have all contributed greatly to the success of this series. Although the comments received so far have generally been favorable, it is nevertheless necessary to analyze and to reassess the current position and the future direction of such a review series. So far, it has been the Editors intention to help disseminate informa tion on the vast domain of drug research, and to provide the reader with a tool with which to keep abreast of the latest developments and trends. The reviews in POR are useful to the non-specialists, who can obtain an overview of a particular field of research in a relatively short time. The specialist readers of POR will appreciate the reviews' comprehensive bibliographies, and, in addition, they may even get fresh impulses for their own research.

The Model Rules of Professional Conduct provides an up-to-date resource for information on legal ethics. Federal, state and local courts in all jurisdictions look to the Rules for guidance in solving lawyer malpractice cases, disciplinary actions, disqualification issues, sanctions questions and much more. In this volume, black-letter Rules of Professional Conduct are followed by numbered Comments that explain each Rule's purpose and provide suggestions for its practical application. The Rules will help you identify proper conduct in a variety of given situations, review those instances where discretionary action is possible, and define the nature of the relationship between you and your clients, colleagues and the courts.

Progress in Drug Research is a prestigious book series which provides extensive expert-written reviews on a wide spectrum of highly topical areas in current pharmaceutical and pharmacological research. It serves as an important source of information for researchers concerned with drug research and all those who need to keep abreast of the many recent developments in the quest for new and better medicines.

Progress in Drug Research is a prestigious book series which provides extensive expert-written reviews on a wide spectrum of highly topical areas in current pharmaceutical and pharmacological research. It serves as an important source of information for researchers concerned with drug research and all those who need to keep abreast of the many recent developments in the quest for new and better medicines.

Progress in Drug Research is a prestigious book series (founded in 1959) which provides extensive expert-written reviews on a wide spectrum of highly topical areas in current pharmaceutical and pharmalogical research. Each volume contains fully cross-referencing indexes which link the volumes together, forming a virtually encyclopaedic work. The series thus serves as an important, time-saving source of information for researchers concerned with drug research and all those who need to keep abreast of the many recent developments in the quest for new and better medicines. Volume 50 in the series includes: P.N. Kaul: Drug discovery: Past, present and future M. Rohmer: Isoprenoid biosynthesis via the mevalonate -- independent route, a novel target for antibacterial drugs G. Edwards and A.H. Weston: Endothelium, -derived hyperpolarizing factor -- a critical appraisal R.W. Rockhold: Glutamatic involvement in psychomotor stimulant action J.M. Colacino and K.A. Staschke: The identification and development of antiviral agents for the treatment of chronic hepatitis B virus infection T.D. Johnson: Polyamines and cerebral ischemia